Healthcare costs associated with bevacizumab and cetuximab in second-line treatment of metastatic colorectal cancer

J Med Econ. 2011; 14(5):542-52

View abstract

Authors

Yang H, Yu AP, Wu EQ, Yim YM, Yu E.